Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alnylam Pharmaceuticals' SEC filings reveal the financial and operational details behind its RNA interference therapeutic development programs. For a clinical-stage biopharmaceutical company with multiple programs spanning rare diseases and cardiometabolic conditions, these regulatory documents contain insights not available through press releases or presentations.
The company's 10-K annual reports break down research and development expenses by therapeutic area, showing which programs receive the most investment. These filings detail clinical trial timelines, regulatory interactions with the FDA and international agencies, and the status of patent applications protecting individual drug candidates. For investors tracking Alnylam's pipeline, the 10-K provides granular disclosure about each program's stage of development, target indications, and potential market opportunities. Manufacturing capacity, supply chain arrangements, and production facility investments also receive detailed treatment in annual filings.
Quarterly 10-Q reports track clinical trial enrollment progress, interim data readouts, and changes to development timelines between annual filings. These documents reveal shifts in resource allocation as programs advance or face setbacks, and they disclose new collaborative agreements or modifications to existing partnerships. For a company advancing multiple RNAi therapeutics simultaneously, the 10-Q shows which programs are progressing and which face delays.
Form 4 insider transaction filings reveal when executives and directors buy or sell Alnylam shares. These transactions sometimes precede material announcements about clinical data or regulatory decisions, making them relevant for investors monitoring company insiders' confidence levels. The 8-K material event reports capture significant developments like clinical trial results, regulatory submissions, debt offerings, and leadership changes as they occur.
AI-powered summaries on this page simplify these complex biotechnology disclosures, highlighting key pipeline updates, financial metrics, and regulatory milestones without requiring hours of manual document review.
Yvonne Greenstreet, Director and CEO of Alnylam Pharmaceuticals (ALNY), reported a mix of equity activity tied to performance compensation and tax withholding on vested awards. On 08/15/2025 she received 14,252 shares upon vesting of 30% of a performance-based stock unit awarded 03/01/2024 after a clinical milestone determination. Following that vesting, multiple automatic sales occurred on 08/18/2025 to satisfy mandatory sell-to-cover tax withholding, reducing her direct holdings from 63,200 to 56,221 shares. The filing also shows 407 shares held indirectly via a managed account and shares acquired under the company 401(k) matching program.
Kevin J. Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals (ALNY), reported insider transactions tied to vested performance-based awards. On 08/15/2025 he was issued 2,851 shares following vesting of 30% of a performance-based stock unit granted 03/01/2024 after a clinical milestone determination. On 08/18/2025 he sold a total of 1,396 shares via multiple transactions under a mandatory sell-to-cover provision to satisfy tax withholding, at weighted sale prices ranging roughly between $447.53 and $456.00 per share. Following these transactions he beneficially owned 23,515 shares directly and an additional 537 shares indirectly through a managed account.
Michael W. Bonney, a director of Alnylam Pharmaceuticals (ALNY), reported transactions on 08/18/2025 under a Rule 10b5-1 trading plan. On that date he acquired 11,250 shares of ALNY common stock at a reported price of $70.20 and sold 11,250 shares at a reported price of $450.00, both transactions recorded under the same date. Following the reported transactions his direct beneficial ownership is listed as 16,804 shares, and he also has 4,000 shares held indirectly by the Michael W. Bonney Revocable Trust. The filing notes the 10b5-1 plan was adopted on November 12, 2024, and that the related stock option was fully vested as of June 3, 2017.
Alnylam Pharmaceuticals (ALNY) filed a Form 144 reporting a proposed sale of 1,455 shares of common stock through UBS Financial Services on 08/19/2025. The filing lists an aggregate market value of $664,935.00 and shows 131,079,015 shares outstanding. The securities were acquired from the issuer as PSU on 08/15/2025 with payment recorded on the same date.
The filer certifies they are not aware of undisclosed material adverse information and discloses no sales of the issuer's securities in the past three months. The filing provides broker details and the exchange (NASDAQ) where the sale is expected to occur.
Alnylam Pharmaceuticals (ALNY) Form 144 summary: This notice reports the proposed sale of 11,250 shares of common stock acquired and to be sold on 08/18/2025. The shares were acquired the same day by exercise of stock options from the issuer and paid in cash. The broker listed is UBS Financial Services, Inc., 11 Madison Avenue, New York. The aggregate market value of the shares at the time of this filing is reported as $5,062,500.00. The filing states the issuer has 131,079,015 shares outstanding and names NASDAQ as the exchange. The filer reports "Nothing to Report" for securities sold by the person in the past three months. The filer also certifies they are not aware of undisclosed material adverse information.
Dennis A. Ausiello, a director of Alnylam Pharmaceuticals, executed multiple equity transactions on 08/14/2025 under a Rule 10b5-1(c) trading plan adopted May 15, 2025. The Form 4 reports exercises of stock options (codes M(1)) for option blocks of 9,000; 5,153; 4,581; 5,228; 4,032; and 3,454 shares at exercise prices ranging from $72.01 to $189.87 per share, each creating corresponding shares of common stock. The filing also shows open-market sales (codes S(1)) of multiple share blocks at weighted-average prices reported in ranges between $430.39 and $443.10 per share. After the reported transactions, the reporting person’s beneficial ownership counts are shown on individual lines (for example, 9,911; 15,064; 19,645; 24,873; 28,905; 32,359; then decreasing after sales to 911). Additionally, 3,500 shares are reported as indirectly owned by a trust for which the reporting person's spouse is trustee. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Ausiello on 08/15/2025.
Alnylam Pharmaceuticals (ALNY) reported a proposed sale under Rule 144 of 31,448 common shares valued at $13,635,538.00 based on the filing. The shares were acquired and are to be sold on 08/14/2025 through UBS Financial Services, Inc. via the exercise of stock options and paid in cash. The filing lists 131,079,015 shares outstanding for the class. The filer reports no shares sold in the past three months. The notice includes the signer’s representation that they are unaware of any undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
